Anzeige
Mehr »
Dienstag, 26.08.2025 - Börsentäglich über 12.000 News
Breaking: AlsetAI zündet nächste Stufe - Neue Allianz mit CHIP Datacentres & Hochkarätige Vorstände markieren Wendepunkt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3C5SS | ISIN: BMG889121031 | Ticker-Symbol: 0RP
Tradegate
26.08.25 | 16:28
1,730 Euro
+2,98 % +0,050
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
TIZIANA LIFE SCIENCES LTD Chart 1 Jahr
5-Tage-Chart
TIZIANA LIFE SCIENCES LTD 5-Tage-Chart
RealtimeGeldBriefZeit
1,5901,65023:00
1,5801,67021:59

Aktuelle News zur TIZIANA LIFE SCIENCES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
14.08.Tiziana Life Sciences Ltd.: Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab for Multiple System Atrophy244BOSTON, Aug. 14, 2025) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human...
► Artikel lesen
TIZIANA LIFE SCIENCES Aktie jetzt für 0€ handeln
11.08.Tiziana to begin testing foralumab in multiple system atrophy4
11.08.Tiziana Life Sciences Ltd.: FDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System Atrophy297NEW YORK, Aug. 11, 2025) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human...
► Artikel lesen
11.08.Tiziana Life Sciences Ltd - 6-K, Report of foreign issuer3
22.07.Tiziana Life Sciences: Lucid Capital Markets startet Coverage mit Kaufempfehlung und sieht Blockbuster-Potenzial19
22.07.Tiziana Life Sciences stock initiated with Buy rating at Lucid Capital Markets2
21.07.Tiziana Life Sciences Ltd.: Tiziana Life Sciences Announces Immunologic Analysis of Nasal Foralumab in Moderate Alzheimer's Patient624NEW YORK, July 21, 2025) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human...
► Artikel lesen
21.07.Tiziana Life Sciences Ltd - 6-K, Report of foreign issuer3
13.06.Tiziana Life Sciences Ltd.: Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center382NEW YORK, June 13, 2025) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human...
► Artikel lesen
13.06.Tiziana shares rise on presentation date for foralumab data4
13.06.Tiziana Life Sciences Ltd.: Tiziana Life Sciences to Present at the Bio International Convention324NEW YORK, June 13, 2025) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human...
► Artikel lesen
13.06.Tiziana Life Sciences Ltd - 6-K, Report of foreign issuer2
23.05.Tiziana Life Sciences Ltd.: Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer's Disease421NEW YORK, May 23, 2025) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human...
► Artikel lesen
23.05.Tiziana Life Sciences Ltd - 6-K, Report of foreign issuer2
15.05.Tiziana Life Sciences Ltd.: Journal of Clinical Nuclear Medicine Publishes Results of Tiziana's Nasal Foralumab in Study Treating Moderate Alzheimer's Disease472NEW YORK, May 15, 2025) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human...
► Artikel lesen
15.05.Tiziana Life Sciences Ltd - 6-K, Report of foreign issuer1
12.05.Tiziana Chairman Gabriele Cerrone Boosts Stake To 37% With Share Purchase3
12.05.Tiziana Life Sciences reports purchase of shares by chairman3
12.05.Tiziana Life Sciences Ltd.: Tiziana Life Sciences Announces Purchase of Shares by Chairman311NEW YORK, May 12, 2025) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human...
► Artikel lesen
09.05.Tiziana posts favorable PET scan data for lead asset in Alzheimer's1
Weiter >>
60 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1